NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.48 +0.04 (+2.78%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compugen Stock (NASDAQ:CGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compugen alerts:Sign Up Key Stats Today's Range$1.42▼$1.4850-Day Range$1.18▼$2.2852-Week Range$1.13▼$2.66Volume47,564 shsAverage Volume393,247 shsMarket Capitalization$132.07 millionP/E Ratio74.00Dividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More… Compugen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreCGEN MarketRank™: Compugen scored higher than 22% of companies evaluated by MarketBeat, and ranked 729th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from ($0.03) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is 74.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is 74.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.18.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.40% of the float of Compugen has been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compugen has recently increased by 4.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.40% of the float of Compugen has been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Compugen has recently increased by 4.30%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Stock News HeadlinesCompugen to Participate in Multiple Virtual Investor Conferences in April 2025March 26, 2025 | prnewswire.comCompugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 25, 2025 | Premier Gold Co (Ad)Calculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)March 6, 2025 | uk.finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | insidermonkey.comCompugen reports Q4 EPS (7c) vs. 11c last yearMarch 4, 2025 | markets.businessinsider.comCompugen Ltd. (CGEN) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comCompugen Reports Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | prnewswire.comSee More Headlines CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.53 at the beginning of the year. Since then, CGEN stock has decreased by 3.3% and is now trading at $1.48. View the best growth stocks for 2025 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Tuesday, March, 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by $0.14. The biotechnology company earned $1.47 million during the quarter, compared to the consensus estimate of $17.47 million. Compugen had a net margin of 2.67% and a trailing twelve-month return on equity of 2.62%. Read the conference call transcript. Who are Compugen's major shareholders? Compugen's top institutional shareholders include Rothschild Investment LLC (0.21%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and Company Calendar Last Earnings3/04/2025Today4/24/2025Next Earnings (Estimated)5/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees70Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+170.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E Ratio74.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,750,000.00 Net Margins2.67% Pretax Margin25.27% Return on Equity2.62% Return on Assets1.36% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual Sales$27.86 million Price / Sales4.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book2.03Miscellaneous Outstanding Shares89,237,000Free Float80,759,000Market Cap$132.07 million OptionableOptionable Beta3.19 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:CGEN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.